What is WellMind?

The WellMind program is designed to facilitate and simplify referrals to appropriate neurology care for patients who present to their primary care providers with clinical signs concerning for early Alzheimer’s disease, and to dramatically shorten the time to specialist consultation, testing and potential treatment. 

WellMind combines blood-based biomarker and genetic risk testing with telemedicine-based neurologic evaluation and management. The goal is to help providers move beyond uncertainty and support patients with clearer information, more informed conversations, and appropriate next steps, while removing the lengthy delays that many patients currently experience when speed to management and treatment is critical. Recently FDA-approved disease modifying therapies for Alzheimer’s disease require appropriate diagnostic testing, specialist evaluation, and close management, and they are most effective when initiated early in the disease course.

WellMind offers two testing options:

WellMind Core includes pTau-217 and GenoRisk (including APOE) testing. pTau-217 is the current gold standard for blood-based diagnostic Alzheimer’s testing.

WellMind Plus includes everything in WellMind Core, plus GFAP and NfL, providing a broader biomarker picture that may help support clinical evaluation.

Patients who prefer not to have full genetic testing may opt out of the GenoRisk assay while still receiving APOE results, which are necessary for management of any infusion-based therpaies that may be subsequently prescribed.